Background: With the cytochrome P450 CYP2C19* 2 (* 2) allelic variant resulting in
complete loss of enzyme function and the CYP2C19* 17 (* 17) variant being linked to …

Context Variants in the CYP2C19 gene influence the pharmacologic and clinical response
to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel. Objective …

Antiplatelet agents are the mainstay treatment in the prevention and management of
atherothrombotic complications. However, a substantial interpatient variability in response to …

INTRODUCTION: The first aim of this study is to evaluate the biological effect of doubling the
maintenance dose of clopidogrel in pre-defined clopidogrel “low responders”, compared to …

Variability in response to antiplatelet therapy can be explained in part by
pharmacogenomics, particularly of the CYP450 enzyme encoded by CYP2C19. Loss-of …

Background: The P2Y 12 adenosine diphosphate (ADP) receptor blocker, clopidogrel, an
essential drug for the prevention of stent thrombosis after percutaneous coronary …

The capacity of clopidogrel to inhibit ADP-induced platelet aggregation shows wide
intersubject variability. To determine whether frequent functional variants of genes coding for …

Clopidogrel is a thienopyridine derivative with ADP-antagonistic activity and is widely used
for the prevention of ischemic events in patients who have suffered a stroke, non-ST …

Clopidogrel, a prodrug, must be activated by hepatic cytochrome P450 (CYP) isoenzymes
before being able to irreversibly block the platelet adenosine 5′-diphosphate (ADP) …

Objectives—Metabolic activity of cytochrome P450 (CYP) 3A4 has been associated with
clopidogrel response variability. Because metabolic activity of CYP3A4 is genetically …